TANDEM DIABETES CARE INC
TNDMNASDAQTrading Snapshot
- Day Range
- $19.46 β $20.25
- 52-Week Range
- $12.26 β $29.65
- Volume (shares)
- 3,356,944
- Avg Volume (shares)
- β
- Shares Outstanding
- 69.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $1.01B
- Last Q Revenue
- $255M
- P/E Ratio
- -21.3
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-0.93
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.8%
TANDEM DIABETES CARE INC
TNDMAbout TANDEM DIABETES CARE INC
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed

Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.

Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thur

Head to Head Contrast: Solventum (NYSE:SOLV) & Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Diabetes Care (NASDAQ: TNDM - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of

Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
[url="]Tandem Diabetes Care, Inc[/url]. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world'